Homology Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Homology Medicines kazanç ve gelirinin sırasıyla yıllık 27.8% ve 13.2% oranında artması tahmin edilirken, EPS'nin yıllık 27.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

27.8%

Kazanç büyüme oranı

27.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	13.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	16 Nov 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:35H - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	2	-37	N/A	N/A	1
12/31/2025	2	-40	N/A	N/A	1
12/31/2024	1	-42	N/A	N/A	2
12/31/2023	1	-113	-96	-96	N/A
9/30/2023	2	-131	-102	-102	N/A
6/30/2023	3	-132	-102	-102	N/A
3/31/2023	3	-126	-109	-109	N/A
12/31/2022	3	-5	-115	-114	N/A
9/30/2022	3	-4	-119	-117	N/A
6/30/2022	4	-1	-119	-117	N/A
3/31/2022	5	-3	-113	-111	N/A
12/31/2021	34	-96	-112	-110	N/A
9/30/2021	34	-92	-94	-91	N/A
6/30/2021	33	-90	-97	-94	N/A
3/31/2021	31	-94	-101	-98	N/A
12/31/2020	3	-129	-98	-94	N/A
9/30/2020	2	-123	-116	-109	N/A
6/30/2020	2	-124	-114	-106	N/A
3/31/2020	2	-115	-113	-99	N/A
12/31/2019	2	-104	-113	-91	N/A
9/30/2019	2	-99	-107	-73	N/A
6/30/2019	3	-83	-98	-61	N/A
3/31/2019	4	-69	-84	-49	N/A
12/31/2018	5	-56	-68	-43	N/A
9/30/2018	4	-49	-22	-12	N/A
6/30/2018	3	-41	-9	-4	N/A
3/31/2018	1	-35	-2	0	N/A
12/31/2017	N/A	-30	5	6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 35H önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 35H önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 35H önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 35H şirketinin gelirinin (yıllık 13.2% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 35H şirketinin gelirinin (yıllık 13.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 35H 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Homology Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2022

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Share price stability

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

No longer forecast to breakeven

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

New 90-day high: €12.09

New 90-day high: €10.86

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

New 90-day low: €7.86

New 90-day low: €8.14

Third quarter 2020 earnings released: US$0.62 loss per share

Revenue beats expectations

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

New 90-day low - €8.36

New 90-day low - €8.97

First half earnings released

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin